Pharmaceutical Product Registration in UAE and Saudi Arabia

To sell a medicine in Saudi Arabia you need a marketing authorisation from the Saudi Food and Drug Authority (SFDA). In the UAE, pharmaceutical regulation has moved to the Emirates Drug Establishment (EDE), which took over functions previously handled by the Ministry of Health and Prevention; confirm the current authority and submission portal before you start.

Both markets expect a dossier in Common Technical Document (CTD) format, evidence of GMP, a local partner and Arabic and English labelling. A GCC centralised route also exists alongside the national procedures.

This is a high-level overview for regulatory affairs staff, especially at Indian manufacturers planning a first GCC filing. Requirements, fees and timelines change, so always check each authority's current guidance.

Who regulates what

Saudi Arabia: the SFDA registers medicines, inspects manufacturers, runs pharmacovigilance and post-market control, and handles pricing. Its guidance is published on its website.

UAE: the EDE is now the federal body for medicines regulation. Emirate-level health authorities still have roles in areas such as facility and professional licensing, so check which body handles each step for your product.

GCC centralised registration: coordinated through the Gulf Health Council, this route offers a joint assessment for participating member states. It sits alongside national routes rather than replacing them, and national steps such as pricing and local listing usually still apply. Check the current procedure and which states take part.

The CTD dossier

The CTD, developed through ICH, organises a dossier into five modules:

• Module 1: regional administrative information, such as application forms, labelling, the CPP, GMP certificates and agent documents. This part differs by country.
• Module 2: quality, nonclinical and clinical overviews and summaries.
• Module 3: quality data on the drug substance and drug product, including manufacture, specifications, validation and stability.
• Module 4: nonclinical study reports.
• Module 5: clinical study reports, including bioequivalence studies for most generic products.

Modules 2 to 5 are harmonised, so a well-built dossier can be reused across markets, while Module 1 is prepared for each authority. Electronic CTD (eCTD) is increasingly expected; confirm whether each authority requires eCTD and which technical specifications apply.

For generics, check early which reference product each authority accepts for bioequivalence. A study against a product sold only in India may not be accepted.

GMP evidence and the CPP

Expect to provide GMP certificates for each manufacturing site, and be ready for an inspection or a request for recent inspection reports from other regulators. What is accepted differs by authority and product type.

The Certificate of Pharmaceutical Product (CPP), in the format of the WHO Certification Scheme, is issued by the regulator in the country of manufacture or export and confirms the product's licence status there. Check whether the authority expects approval in the country of origin or in a reference market, and how the CPP must be legalised.

Stability for hot climates

ICH and WHO stability guidance groups the world into climatic zones. Zone IVa (hot and humid) uses long-term storage at 30°C/65% RH, and Zone IVb (hot and very humid) uses 30°C/75% RH.

The GCC generally expects stability data suited to hot climates. Confirm the zone and conditions each authority requires before you lock your study design, because a late long-term study delays the filing. ICH stability guidance is being revised, so check the current version.

Labelling, local agent and pricing

Labelling: outer and inner labels and the patient information leaflet are generally required in Arabic and English. Follow the authority's labelling guidance on content, format and artwork approval.

Local agent or marketing authorisation holder: foreign manufacturers usually need a locally licensed agent, scientific office or marketing authorisation holder to submit and maintain the registration. Agree responsibilities in writing, including variations, pharmacovigilance and recalls.

Pricing: price approval is a separate step from the scientific assessment. Plan for it, because a registered product cannot launch until pricing and any listing steps are complete.

Registration steps at a glance

After approval: pharmacovigilance and variations

Approval starts a set of ongoing duties. Authorities expect the marketing authorisation holder to run a pharmacovigilance system, typically with a qualified person for pharmacovigilance (often required locally), reporting of serious adverse reactions within set timeframes, periodic safety reports and risk management plans where requested. SFDA publishes its own good pharmacovigilance practice guidelines and GCC-level guidance also exists; check the current versions.

Changes such as a new manufacturing site, a specification change or a new pack size need a variation, classified under the authority's variation guidance, before implementation. Registrations also need renewal.

Worked example: an Indian generic manufacturer's first GCC filing

A mid-sized generics manufacturer in Vadodara, with a WHO-GMP certificate and exports to African markets, plans its first GCC filing: amlodipine tablets for Saudi Arabia and the UAE. The regulatory affairs lead starts with a gap analysis of the existing CTD dossier:

• Stability: long-term data exist at 30°C/65% RH only. The team checks each authority's requirements and starts an additional study at 30°C/75% RH in the commercial pack.
• Bioequivalence: the study used an Indian reference product. The team checks which reference product each authority accepts and budgets for a new study if needed.
• Module 1: new application forms, Arabic and English artwork and a CPP from the Indian authorities.
• Local partners: a licensed agent in each country, with an agreement covering submissions, queries, pharmacovigilance, recalls and pricing.
• Pharmacovigilance: the global system lacks GCC-specific procedures, so local arrangements are planned.

With its agents, the company compares the national and centralised routes before choosing. The biggest risks to timing are stability and bioequivalence, not paperwork, so the team checks them first.

Common mistakes

• Assuming an Indian or WHO dossier can be submitted unchanged.
• Discovering late that stability conditions or the bioequivalence reference product do not meet GCC expectations.
• Treating Arabic labelling as a translation job rather than regulated artwork.
• Signing an agent agreement that does not define pharmacovigilance and recall duties.
• Leaving pricing out of launch planning.
• Using pre-EDE guidance for UAE filings.

Key takeaway: Build harmonised CTD Modules 2 to 5 once, then tailor Module 1, stability, bioequivalence, labelling and local representation for each GCC authority. Confirm every requirement with SFDA, the EDE or the Gulf Health Council before you commit resources.

Frequently Asked Questions

Who registers medicines in the UAE?

Medicines regulation in the UAE has been consolidated under the Emirates Drug Establishment, which took over pharmaceutical functions previously handled by the Ministry of Health and Prevention. Emirate-level authorities still have roles in some areas, such as facility licensing. Because the change is recent, confirm the current authority, guidance and submission portal before preparing a dossier.

What is GCC centralised registration?

It is a route coordinated through the Gulf Health Council that allows a joint assessment of a product for participating GCC member states. It sits alongside national registration rather than replacing it, and national steps such as pricing and local listing generally still apply. Check the current procedure, eligibility and participating states with the Gulf Health Council.

Do I need a local agent to register a medicine in Saudi Arabia?

Foreign manufacturers generally need a locally licensed agent, scientific office or marketing authorisation holder in Saudi Arabia to submit and maintain registrations, handle queries and support pharmacovigilance and recalls. The exact requirements are set by the SFDA, so confirm them in current guidance and define every responsibility clearly in your agreement.

Which stability zone applies to GCC countries?

GCC authorities generally expect stability data suited to hot climates, which in ICH and WHO terms means Zone IVa (30°C/65% RH) or Zone IVb (30°C/75% RH) long-term conditions. Requirements can differ by authority and product, so confirm the expected zone with each regulator before designing or extending your stability programme.

Next steps

To build a working knowledge of GCC dossiers, authorities and post-approval duties, see Regulatory Affairs for Pharma & Medical Devices in the GCC. For the safety reporting side of a marketing authorisation, Pharmacovigilance & Drug Safety Essentials is a practical next step. You can also speak to a counsellor.

Related reading: pharmacovigilance career guide and adverse event vs serious adverse event.